Stepping away from its billions-of-years-old role as a genetic "blueprint," DNA is now embarking on a new journey as an active "field agent" within cells. This research by a team led by Professor ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka factors, proteins ...